{
"id":"mk19_b_rm_q015",
"number":15,
"bookId":"rm",
"correctAnswer":"A",
"title":"Question 15",
"stimulus":[
{
"type":"p",
"hlId":"28a284",
"children":[
"A 36-year-old woman is evaluated in the emergency department after experiencing a tonic-clonic seizure. For 1 week she has had severe headaches. Eight months ago, Raynaud phenomenon of the hands and feet developed. Current medication is sustained-release nifedipine."
]
},
{
"type":"p",
"hlId":"b83987",
"children":[
"On physical examination, temperature is 37.0 °C (98.6 °F), blood pressure is 240/120 mm Hg, pulse rate is 90/min, respiration rate is 18/min, and ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Oxygen saturation, arterial (ambient air)",
"children":[
"oxygen saturation"
]
},
" is 96% with the patient breathing ambient air. The skin over the hands, forearms, trunk, lower legs, and feet is tight and appears thickened. The fingers on both hands show cyanosis. No nuchal rigidity is noted, and findings on neurologic examination are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f1fae6",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hematocrit",
"children":[
"Hematocrit"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"65d1d3",
"class":"cell text l",
"children":[
"33%"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"9d81d4",
"class":"cell text l",
"children":[
"Leukocyte count"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fcac73",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Platelet count",
"children":[
"Platelet count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e7710b",
"class":"cell text l",
"children":[
"90,000/μL (90 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"f36a04",
"class":"cell text l",
"children":[
"2.4 mg/dL (212.2 μmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ecdf9a",
"class":"cell text l",
"children":[
"2+ protein; no blood or casts"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"b770a3",
"children":[
"Peripheral blood smear reveals diminished platelet numbers and schistocytes."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"f79f7a",
"children":[
"Which of the following is the most appropriate intravenous treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Captopril"
}
},
{
"letter":"B",
"text":{
"__html":"Cyclophosphamide"
}
},
{
"letter":"C",
"text":{
"__html":"Methylprednisolone"
}
},
{
"letter":"D",
"text":{
"__html":"Metoprolol"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"ca89e9",
"children":[
"Patients with scleroderma renal crisis may exhibit anemia, thrombocytopenia, proteinuria, and schistocytes on the peripheral blood smear."
]
},
{
"type":"keypoint",
"hlId":"333145",
"children":[
"ACE inhibitors (typically captopril) can be lifesaving in patients with scleroderma renal crisis, and dosages should be titrated to control blood pressure regardless of serum creatinine level."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"a787b4",
"children":[
"The most appropriate intravenous treatment is captopril (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). This patient has hypertensive crisis due to underlying systemic sclerosis, which is best treated with an ACE inhibitor. Captopril in particular is useful in this situation because it has a relatively short half-life and can be titrated rapidly to control blood pressure. Scleroderma renal crisis can occur in limited or diffuse cutaneous systemic sclerosis but is more common in diffuse disease. Risk factors include recent onset of systemic sclerosis (≤4 years), diffuse skin disease, presence of anti-RNA polymerase III antibodies, and recent use of glucocorticoids. The pathophysiology is thought to be related to endothelial injury leading to vascular constriction, intimal thickening, and fibrin deposition, with endothelin 1 playing an important role in this process. Also important in the pathophysiology is activation of the renin-angiotensin-aldosterone system; interrupting this pathway has been a key to therapy. Manifestations of scleroderma renal crisis are those seen in patients with hypertensive emergency, such as headache, encephalopathy, retinopathy, acute kidney injury, and heart failure. Anemia, thrombocytopenia, and proteinuria are common laboratory features. Evidence of microangiopathic hemolytic anemia with schistocytes on the peripheral blood smear is a clue to the diagnosis. ACE inhibitors are disease-modifying agents for this potentially fatal complication, regardless of the serum creatinine level. Patients may need temporary dialysis, and kidney function may improve during therapy for up to 24 months after presentation. Prophylactic use of ACE inhibitors does not prevent scleroderma renal crisis and may lead to poorer renal outcomes."
]
},
{
"type":"p",
"hlId":"984d3b",
"children":[
"Immunosuppression has no role in modifying the course of scleroderma renal crisis, so neither intravenous cyclophosphamide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") nor intravenous methylprednisolone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is indicated. Recent use of glucocorticoids is a risk factor for scleroderma renal crisis; thus, glucocorticoids should be avoided."
]
},
{
"type":"p",
"hlId":"1a7342",
"children":[
"Intravenous metoprolol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") does not address the pathophysiology of scleroderma renal crisis. β-Blockers are generally not first-line therapy for most causes of hypertensive emergencies other than episodes associated with eclampsia/preeclampsia, acute coronary syndrome, and aortic dissection; in these cases, labetalol or a short-acting agent such as esmolol is typically preferred to metoprolol."
]
}
],
"relatedSection":"mk19_b_rm_s10_4",
"objective":{
"__html":"Treat scleroderma renal crisis."
},
"references":[
[
"Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: state of the art. Autoimmun Rev. 2018;17:882-889. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30005860",
"target":"_blank"
},
"children":[
"PMID: 30005860"
]
},
" doi:10.1016/j.autrev.2018.03.012"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":63,
"B":11,
"C":22,
"D":4,
"E":0
},
"hlIds":[
"28a284",
"b83987",
"a462a3",
"f1fae6",
"65d1d3",
"9d81d4",
"960b44",
"fcac73",
"e7710b",
"f461b2",
"f36a04",
"747c2a",
"ecdf9a",
"b770a3",
"f79f7a",
"ca89e9",
"333145",
"a787b4",
"984d3b",
"1a7342"
]
}